A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This trial is an open, phase II clinical study. The study is divided into two parts: A and B,
and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in
patients with locally advanced or metastatic urothelial cancer, determine the recommended
dose of midoral AZD4547 combined with Tislelizumab in a Chinese patient population. Part B
study will evaluate the efficacy of this recommended dose combined with Tislelizumab in
patients with locally advanced or metastatic urothelial cancer with FGFR2 / 3 alterations ,
and will also further evaluate the safety, tolerability, and PK and PD characteristics of
AZD4547 in combination with Tislelizumab.